TY - JOUR AU - Dixon, SC AU - Nagle, CM AU - Wentzensen, N AU - Trabert, B AU - Beeghly-Fadiel, A AU - Schildkraut, JM AU - Moysich, KB AU - deFazio, A AU - Australian Ovarian Cancer Study Group AU - Risch, HA AU - Rossing, MA AU - Doherty, JA AU - Wicklund, KG AU - Goodman, MT AU - Modugno, F AU - Ness, RB AU - Edwards, RP AU - Jensen, A AU - Kjær, SK AU - Høgdall, E AU - Berchuck, A AU - Cramer, DW AU - Terry, KL AU - Poole, EM AU - Bandera, EV AU - Paddock, LE AU - Anton-Culver, H AU - Ziogas, A AU - Menon, U AU - Gayther, SA AU - Ramus, SJ AU - Gentry-Maharaj, A AU - Pearce, CL AU - Wu, AH AU - Pike, MC AU - Webb, PM Y2 - 2020/12/17 Y1 - 2017/04/25 SN - 0007-0920 UR - http://hdl.handle.net/11343/254856 AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited. METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths). RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)). CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted. LA - eng PB - Springer Science and Business Media LLC T1 - Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. DO - 10.1038/bjc.2017.68 IS - British Journal of Cancer VL - 116 IS - 9 SP - 1223-1228 L1 - /bitstream/handle/11343/254856/PMC5418444.pdf?sequence=1&isAllowed=y ER -